RSS

Gram-negative multidrug-resistant pathogens

The AMR Centre (AMRC) and EligoChem have entered into an agreement for the co-development of antimicrobial peptides to treat drug-resistant Gram-negative bacteria, such as E. coli. Read more

News

A specialist in therapeutic approaches to treat resistant bacterial infections, Mutabilis has been selected to join the European consortium ENABLE — aimed at developing antibiotics to tackle infections caused by multi-resistant gram-negative bacteria Read more

News

Biopharmaceutical company, Antabio, has completed a €7.3 million series A financing round for the development of novel therapies to treat drug-resistant gram-negative infections. Read more

News

Cheshire-based R&D facility for new antibiotics and diagnostics, the AMR Centre, has signed a deal with US biotech company, Microbiotix, for the co-development of a bacterial virulence drug candidate. Read more

News

Polyphor has been awarded with its first milestone payment from the Wellcome Trust ahead of schedule for the development of novel antibiotics against Gram-negative multidrug-resistant pathogens. Read more

News